Of the 886 patients, 442 were randomly assigned to the combination group, and 444 were assigned to receive sunitinib; 560 (63.2%) patients had PD-L1 positive tumor defined as ≥1% of immune cells staining positive within the tumor area with Ventana PD-L1 (SP263) assay [15]. This evidence concerns the gene CD274 and neoplasm.